Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Lauxera Capital Partners is an independent, international investment fund established in 2020, focusing on growth-stage companies in the Healthtech sector. The firm was founded by Samuel Levy, Pierre Moustial, and Alex Slack, who collectively bring over 50 years of experience in healthtech investing. Lauxera operates from its offices in Paris, France, and San Francisco, USA, managing over €800 million in assets across its funds.
The firm’s inaugural fund, Lauxera Growth I, was followed by Lauxera Growth II, which closed in 2025 with over €400 million raised. This fund is dedicated to late-stage European healthtech companies with global expansion potential. Lauxera has achieved notable milestones, including a significant exit with the acquisition of OrganOx by Terumo Group for $1.5 billion in August 2025, marking one of the largest European medtech exits of the year.
Lauxera Capital Partners invests primarily in the Healthtech sector, targeting companies that have achieved breakeven or early profitability. The firm focuses on a variety of sectors, including medical devices, digital health, pharma services, life science tools, diagnostics, and healthtech IT and data. Investment checks range from $22 million to $110 million, allowing Lauxera to support companies at critical growth stages.
The firm emphasizes commercial execution as a primary driver of value creation, seeking businesses with proven commercial traction. Lauxera's geographic focus includes North America and Europe, with a particular interest in European companies poised for global expansion. The firm aims to catalyze growth through innovation, commercial investment, business development, and talent acquisition, leveraging its extensive network and expertise.
Lauxera Capital Partners has built a diverse portfolio of 12 companies within the Healthtech sector. Notable investments include:
Samuel Levy: Co-founding Partner; physician-turned-entrepreneur with extensive experience in healthcare investments.
Pierre Moustial: Co-Founder; veteran pharmaceutical executive and former CEO with a strong background in healthtech.
Alex Slack: Co-Founding Partner; experienced healthcare investment professional with a focus on growth-stage companies.
Pauline Bowman: Compliance Officer & Middle Office Manager; oversees compliance and operational functions.
Lise de Courville: Head of Investor Relations & ESG; manages investor relations and environmental, social, and governance initiatives.
Victor Decrion: Managing Partner; leads investment strategies and portfolio management.
Edoardo Fracchia: Partner; focuses on investment opportunities in healthtech.
Rémi Joubert: Senior Associate; supports investment analysis and portfolio management.
Delphine Leduc: Office Manager; oversees administrative functions.
Alessandra Malaval: Investment Manager; responsible for sourcing and managing investments.
Adrian Péfau: Analyst; conducts market research and financial analysis.
Anaïs Raevel: Analyst; assists in investment evaluations and due diligence.
Victoire Ribert: Investment Manager; focuses on portfolio company support and growth strategies.
Pauline Ritter: Principal; leads investment initiatives and strategy development.
Anna Yang: CFO & Head of Operations; manages financial operations and strategic planning.
To pitch Lauxera Capital Partners, founders should send an email to contact@lauxera.com. It is recommended to include a comprehensive pitch deck that outlines the business model, market opportunity, and financial projections. Founders should expect a response within a few weeks, depending on the volume of inquiries.
Warm introductions are preferred, but not mandatory. The pitch deck should clearly articulate the startup's value proposition and growth strategy, as Lauxera focuses on companies that have achieved early profitability.
In August 2025, Lauxera Capital Partners achieved a significant milestone with the acquisition of its portfolio company, OrganOx, by Terumo Group for $1.5 billion. This exit is noted as one of the largest European medtech exits of the year.
In 2025, Lauxera closed its second fund, Lauxera Growth II, raising over €400 million to continue its focus on late-stage European healthtech companies. This fund aims to support businesses poised for global expansion.
Throughout 2023, Lauxera has been actively updating its portfolio and maintaining a presence in the media, with regular updates on investments and company activities available on their website.
What are Lauxera Capital Partners' investment criteria?
Lauxera Capital Partners focuses on growth-stage healthtech companies that have achieved early profitability. The firm invests in sectors such as medical devices, digital health, and diagnostics, with check sizes ranging from $22 million to $110 million.
How can I pitch to Lauxera Capital Partners?
Founders can reach out via email at contact@lauxera.com. It is advisable to include a detailed pitch deck that outlines the business model, market opportunity, and financial projections.
What makes Lauxera Capital Partners different from other investors?
Lauxera Capital Partners combines over 50 years of experience in healthtech investing, focusing on companies at the early profitability stage. The firm emphasizes commercial execution and offers extensive support in business development and talent acquisition.
What is the geographic scope of Lauxera's investments?
The firm primarily invests in North America and Europe, with a particular focus on European companies that have global expansion potential.
What is Lauxera's post-investment involvement like?
Lauxera Capital Partners actively engages with its portfolio companies, providing support in innovation, commercial investment, and business development to help them achieve their growth objectives.
What is the size of Lauxera's funds?
Lauxera Capital Partners manages over €800 million in assets, with its second fund, Lauxera Growth II, closing at over €400 million in 2025.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.